GLP-1 hair loss timeline: when it starts, peaks, and recovers (2026)

Why GLP-1s cause hair shedding (a why the timing matters)

Hair shedding on GLP-1 medications is well-documented and appears in roughly 3-5% of patients in clinical trial data (STEP series for semaglutide, SURMOUNT series for tirzepatide). The mechanism is NOT direct drug toxicity to hair follicles. Instead, it's and physiologic response to rapid weight loss called telogen effluvium.

Hair follicles cycle through three phases: anagen (active growth, ~85% of follicles at any time), catagen (transition, ~1%), and telogen (resting, ~10-15%). And significant physiologic stressor — rapid weight loss being one of the most common — pushes and larger fraction of follicles from anagen simultaneously into telogen. Those follicles all shed about 3-4 months later, all at once, which is why patients describe the shedding as 'sudden' even though the trigger occurred months earlier.

Week-by-week timeline

Months 0-2 (treatment initiation): No hair changes. Drug is titrating, weight loss is modest.

Months 2-3 (rapid weight loss begins): Still no visible hair changes. Follicles entering telogen — invisible to the patient.

Months 3-5 (shedding window opens): Daily shedding noticeably increases. Most patients report seeing more hair in the shower drain, on the pillow, in the brush. Hair density on the scalp can look subjectively thinner.

Months 4-6 (peak shedding): Daily shedding rate peaks. This is the most psychologically difficult phase — visible thinning in some patterns (often temples and crown most noticeable).

Months 6-9 (recovery phase): Daily shedding rate gradually returns to normal. New hair growth (short, fine, and appearing as 'baby hairs' at the hairline and part) becomes visible.

Months 9-12+ (density restoration): Visible thickness returns as new hair lengthens. Full restoration to baseline density is the norm.

Who's at higher risk and why

Risk factors that increase the magnitude of GLP-1-associated shedding: rapid weight loss (>2% of body weight per month consistently); lower protein intake during weight loss; pre-existing low iron stores (ferritin <40 ng/mL); concurrent stressors (major life event, illness, pregnancy/postpartum); and personal history of telogen effluvium from prior weight loss attempts.

Notably, the absolute amount of weight lost matters less than the rate. And patient losing 60 lb over 12 months at 5 lb/month is at lower risk than and patient losing 30 lb over 4 months at 7.5 lb/month, even though the absolute loss is smaller. This is also why bariatric surgery patients see similar shedding patterns around months 3-5 post-op.

What actually helps (evidence-graded)

Strong evidence: adequate protein intake (1.2-1.6 g per kg body weight daily) reduces hair shedding magnitude during rapid weight loss. Most rapid weight-loss patients are inadvertently under-eating protein because portion sizes shrink. And scoop of whey protein or and serving of Greek yogurt added to meals can close the gap.

Moderate evidence: ferritin replacement IF deficient. Low iron stores worsen shedding and prolong recovery. Routine supplementation in the absence of deficiency does NOT help and can cause GI side effects. Check ferritin (not just hemoglobin) before supplementing.

Weak evidence: minoxidil (Rogaine) 5% topical or 2.5 mg oral can be considered if shedding is severe and emotionally distressing. Evidence base for telogen effluvium is small but suggestive. Effect onset takes 3-6 months; benefit is marginal in most cases.

No evidence: biotin supplementation. Despite mass-market hair-vitamin claims, biotin doesn't help telogen effluvium and can interfere with lab testing (thyroid panels, troponin). Discontinue 48-72 hours before any blood work.

When to worry (a when not to)

The hair changes that warrant clinical workup are NOT typical telogen effluvium: patchy hair loss (suggests alopecia areata), scarred-looking hairless areas (suggests scarring alopecia), accelerated frontal hairline recession (suggests androgenetic alopecia unmasking), and shedding that persists beyond 9-10 months from onset.

Routine telogen effluvium from GLP-1 doesn't require dermatology referral. The expected pattern is: diffuse shedding, no scarring, symmetric, and self-limiting. If your hair loss matches this pattern, time and protein are the main interventions. The harder work is psychological — knowing that the shedding is temporary doesn't always make it less distressing in the moment.